Founded by a group of physicians, CERC has a wide experience in clinical research. Their renown and expertise in this field have enabled them to generate optimal interaction with their industrial partners and other medical research teams focusing on the development of innovative techniques, concepts and treatments.
They provide unparalleled guidance and expert support in a broad range of clinical trials dedicated to the assessment of interventional coronary and peripheral revascularisation, structural and valvular heart disease treatments and adjunctive pharmacology.
Its objectives are to underpin European clinical trials and academic leadership, act as a global CRO and support young scientific leaders.
The CERC’s industrial partners attach great importance to finding cost-effective models which do not compromise quality.
Learn more: www.cerc-europe.org
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
June 27, 2024
25 September 2024 from 4:00PM to 5:30PM (CEST) Webinar Overview It has been demonstrated that using standards from the start of clinical research studies (i.e. protocol and CRF development) can save significant time and resources and results in higher quality research. Unfortunately, it is not always clear how to select the appropriate standards for the […]
June 27, 2024
Applied Clinical Trials Online ACT: How can data management challenges be addressed? Specifically, is there any opportunity to address them with artificial intelligence (AI)? Lacroix: There is a lot of opportunity across the life cycle to assist with this and it’s interesting because historically it was always: we want to throw people at some of […]
June 27, 2024
Fiercebiotech Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years prior to launch. This strategy should focus on addressing the nuanced market access challenges for such treatments, including but not limited to, distribution network design, tailored commercial site engagement, […]